Klinik und Poliklinik für Neurologie, Charité Universitätsmedizin Berlin, Germany.
Curr Opin Neurol. 2011 Feb;24(1):75-80. doi: 10.1097/WCO.0b013e3283424c53.
Large clinical trials have clearly demonstrated that statins reduce the risk of first and recurrent stroke. This review aims to highlight the current findings and recent developments in this field.
In addition to risk reduction, statins may also improve stroke outcome, even when administered after the event. Due to the multitargeted vasoprotective effects of statins, statins may be beneficial in various conditions and disorders in which acute and chronic endothelial dysfunction play a key role. Vice-versa, abrupt interruption of statin therapy following acute cerebrovascular or cardiovascular events may impede vascular function and increase morbidity and mortality. Furthermore, statins could serve as an adjuvant for enhancing the efficacy of thrombolytic therapy and other promising neuroprotective compounds, as it stabilizes endothelial function and additionally exerts profibrinolytic, immunomodulatory, and antioxidant effects. However, so far, there are only limited clinical data on the effect of statin therapy on stroke outcome.
Statins are emerging as a new and promising avenue for the prevention and potentially treatment of ischemic stroke. New clinical trials are necessary to clarify the impact of acute statin treatment on stroke outcome.
大型临床试验清楚地表明，他汀类药物可降低首次和复发性中风的风险。本综述旨在强调该领域目前的发现和最新进展。
除了降低风险外，他汀类药物甚至在事件发生后给药也可能改善中风的结果。由于他汀类药物具有多靶点血管保护作用，他汀类药物可能对急性和慢性内皮功能障碍起关键作用的各种疾病和病症有益。相反，急性脑血管或心血管事件后他汀类药物治疗的突然中断可能会阻碍血管功能并增加发病率和死亡率。此外，他汀类药物可以作为增强溶栓治疗和其他有前途的神经保护化合物疗效的辅助手段，因为它稳定了内皮功能，并且还具有抗纤维蛋白溶解、免疫调节和抗氧化作用。然而，到目前为止，关于他汀类药物治疗对中风结果的影响的临床数据有限。
他汀类药物作为预防和潜在治疗缺血性中风的新方法和有前途的方法正在出现。有必要进行新的临床试验来阐明急性他汀类药物治疗对中风结果的影响。
